Galenicum Health Peru launches new intensive care business unit
September 7, 2017
Galenicum Health Peru has launched Caspofungin and Tigecycline. These two products mark the start of a new unit of anti-infective products for intensive care.
Tigecycline 50 mg lyophilized powder for solution for perfusion is an antibacterial in the tetracycline group for systemic use. Tigecycline is indicated for the treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections in adults.
Caspofungin 50 mg and 70 mg powder for concentrate for solution for perfusion is a systemic antimycotic that belongs to the echinocandins group. Caspofungin is indicated for the treatment of invasive candidiasis in adult or pediatric patients, invasive aspergillosis in adult or pediatric patients that are refractory or intolerant to amphotericin B, lipid formulations of amphotericin B and / or itraconazole. In addition, it is indicated for empirical treatment of apparent fungal infections (such as Candida or Aspergillus) in adult or pediatric patients with neutropenia and fever.
These products will be marketed in the main clinics and hospitals of the Ministry of Health and Social Security.
The launch of this new business unit will strengthen the company’s oncology portfolio.